Sugi Predict

Sugi Predict / Targets / NOXO1

NOXO1

NADPH oxidase organizer 1 · Q8NFA2 · NOXO1 on Sugi Atlas →

437 patent compounds predicted against NOXO1, 276 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL20161540 SCHEMBL20161540 0.58 1/20
SCHEMBL18081133 SCHEMBL18081133 0.58 1/20
SCHEMBL23365917 SCHEMBL23365917 0.57 1/20
SCHEMBL20161403 SCHEMBL20161403 0.57 1/20
SCHEMBL23365916 SCHEMBL23365916 0.56 1/20
SCHEMBL13528032 SCHEMBL13528032 0.56 1/20
SCHEMBL18705339 SCHEMBL18705339 0.56 1/20
SCHEMBL23365942 SCHEMBL23365942 0.56 1/20
SCHEMBL19326743 SCHEMBL19326743 0.55 1/20
SCHEMBL23365946 SCHEMBL23365946 0.55 1/20
SCHEMBL19261534 SCHEMBL19261534 0.55 1/20
SCHEMBL10246039 SCHEMBL10246039 0.55 1/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL19991675) 0.55 1/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL30606899) 0.55 1/20
SCHEMBL19991674 SCHEMBL19991674 0.54 1/20
SCHEMBL9979905 SCHEMBL9979905 0.54 1/20
SCHEMBL24425712 SCHEMBL24425712 0.54 1/20
SCHEMBL31135780 SCHEMBL31135780 0.54 1/20
SCHEMBL13528033 SCHEMBL13528033 0.54 1/20
SCHEMBL15786481 SCHEMBL15786481 0.53 1/20

Clinical trials — most relevant to NOXO1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE PHASE2UNKNOWN
Endothelial Dysfunction and Oxidative Stress in Children With Sleep Disordered Breathing. PHASE1/PHASE2COMPLETED
Salt-Sensitivity and Immunity Cell Activation PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease PHASE1/PHASE2RECRUITING
Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers PHASE1COMPLETED
NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM PHASE1WITHDRAWN
The Effect of Antioxidants on Skin Blood Flow During Local Heating PHASE1COMPLETED
Role of NADPH Oxidase in Microvascular Dysfunction Following GDM EARLY_PHASE1RECRUITING
GSNOR Phenotyping/GSNO Challenge in Severe Asthma EARLY_PHASE1COMPLETED
Endometriosis and Microvascular Dysfunction: Role of Inflammation EARLY_PHASE1RECRUITING
Covid-19: Possible Role of Neutrophil Extracellular Traps nanUNKNOWN
NCF Gene & TNFSF4 in SLE Patients nanUNKNOWN
Early Regenerative Intervention for Post-Traumatic Osteoarthritis nanUNKNOWN
Role of Nox2 in CNI-induced Renal Fibrosis nanCOMPLETED
Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19 nanCOMPLETED
Anti-inflammatory Effects of Fiber nanCOMPLETED
Effect Inhaled Nitric Oxide in Adult Liver Transplant nanNOT_YET_RECRUITING
Immunological Profile and Clinical Characteristics of Children Diagnosed With Chronic Granulomatous Disease nanUNKNOWN
A Feasibility Study: Assessing Photobiomodulation in Myalgic Encephalomyelitis nanUNKNOWN
Molecular Hydrogen Inhalation: Effects on Health, Exercise Capacity and Inflammatory Response - in Vivo/in Vitro Studies nanNOT_YET_RECRUITING
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS) nanUNKNOWN
External Nitric Oxide Measurement Through SNO Degradation nanENROLLING_BY_INVITATION
Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program) nanCOMPLETED
Reactive Oxygen Species Following Aortic Valve Replacement nanCOMPLETED
Flow Mediated Dilation in Association With Hyperuricemia nanUNKNOWN
Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis nanCOMPLETED
Oxidative Stress and Haemostasis Abnormalities in Cirrhosis nanUNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium nanCOMPLETED
Neutrophil Oxidative Burst in Early and Late Onset Pediatric Inflammatory Bowel Disease nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NOXO1 binder may also engage these)

ProteinNameSimilarity
Q8VCM2 — 0.995 Q8VCM2 →
Q7L591 — 0.982 Q7L591 →
B2RYG7 — 0.982 B2RYG7 →
Q7Z736 — 0.981 Q7Z736 →
Q3B7L1 — 0.981 Q3B7L1 →
Q3UR97 — 0.980 Q3UR97 →
Q8VCE9 — 0.979 Q8VCE9 →
Q9QZK7 — 0.978 Q9QZK7 →
Q6ZW31 — 0.977 Q6ZW31 →
A3R064 — 0.976 A3R064 →
Q91WA6 — 0.975 Q91WA6 →
Q4QQV2 — 0.975 Q4QQV2 →
Q1RMU7 — 0.975 Q1RMU7 →
Q148E7 — 0.975 Q148E7 →
Q14B98 — 0.974 Q14B98 →
RIN1 Ras and Rab interactor 1 (Ras inhibitor JC99) 0.974 landscape →
O60496 — 0.974 O60496 →
Q9NRS6 — 0.974 Q9NRS6 →
Q8IYJ3 — 0.974 Q8IYJ3 →
Q5TJE5 — 0.974 Q5TJE5 →
Q921Q7 — 0.974 Q921Q7 →
Q3UYI5 — 0.973 Q3UYI5 →
Q8IW93 — 0.973 Q8IW93 →
A7MBB8 — 0.972 A7MBB8 →
SHARPIN Sharpin (Shank-associated RH domain-interacti 0.972 landscape →
Q3MIN7 — 0.972 Q3MIN7 →
O70469 — 0.971 O70469 →
Q8N398 — 0.971 Q8N398 →
Q969T3 — 0.971 Q969T3 →
Q0IIA6 — 0.971 Q0IIA6 →